Fresita Proteins Rights Issue: ₹90 Crore Terms Due Oct 26

Rights Issue Committee Meeting Scheduled

Fresita Proteins Limited is scheduled to hold a meeting of its Rights Issue Committee on October 26, 2026, to finalise terms for a proposed equity rights issue of up to ₹90 crore. The company informed BSE about the meeting on October 21 under the applicable listing disclosure requirements. Key decisions expected from the committee include the issue price, rights entitlement ratio, payment mechanism and record date. These terms will determine how existing shareholders can participate in the proposed capital raise. Fresita Proteins was previously known as Sarda Proteins Limited.

Proposed Fundraising Amount

The proposed issue being considered by the committee is capped at ₹90 crore. The equity shares proposed under the issue carry a face value of ₹10 each, according to the company information available. A rights issue allows eligible shareholders to subscribe to new shares in proportion to their existing holdings, subject to the final entitlement ratio. The final number of shares cannot be determined until the issue price and ratio are approved. The company has not yet disclosed those details in the cited committee-meeting intimation.

Earlier Board Approval Provides Context

The capital-raising process follows an August 5, 2026 board approval for a rights issue. The initial corporate-action information described the approved issue size as not exceeding ₹100 crore and stated that a committee had been formed to oversee the process. The subsequent October committee notice refers to a proposed raise of up to ₹90 crore. The available disclosures therefore show an earlier broader board-approved ceiling and a lower amount under consideration for the terms meeting. Investors will need the committee outcome to confirm the final issue size and structure.

Terms Yet to Be Decided

The committee is expected to decide the rights issue price and the ratio of shares offered to eligible shareholders. It is also expected to set the record date, which identifies shareholders entitled to receive rights entitlements. The payment mechanism and timing of the issue are also listed for consideration. Until these decisions are announced, shareholders do not have the information needed to assess the subscription cost or their potential allocation. The company has said the process will be undertaken in line with the Companies Act, 2013, and SEBI's Issue of Capital and Disclosure Requirements Regulations, 2018.

Trading Window Closure Announced

Fresita Proteins has closed its trading window from October 26, 2026, until 48 hours after the conclusion of the board meeting. The restriction applies to directors, designated persons and their immediate relatives. The closure has been announced under the company's code of conduct for prevention of insider trading. Such restrictions are intended to prevent trading while potentially price-sensitive information, including fundraising terms, is being considered. The reopening date will depend on when the meeting concludes and the resulting information is disclosed.

Shareholders Approved Higher Borrowing Powers

At the company's 35th Annual General Meeting held on September 30, 2026, shareholders approved borrowing powers of up to ₹1,000 crore through a special resolution. Shareholders also approved loans, guarantees and investments up to ₹1,000 crore under Section 186 of the Companies Act, 2013. The AGM was conducted through video conference. The meeting also adopted audited standalone financial statements for FY2025-26, approved the reappointment of the statutory auditor and appointed a new director. These approvals expand the company's authorised financial flexibility but do not indicate borrowing that has already taken place.

Key Facts at a Glance

What the Rights Issue Means for Shareholders

A rights issue provides existing shareholders an opportunity to subscribe to fresh equity before the company offers shares more widely. Participation will depend on the final issue price, entitlement ratio and record date. Shareholders who do not subscribe may face dilution of their percentage holding after the new shares are issued, depending on the final structure and participation levels. Rights entitlements may also have value depending on the terms and applicable market arrangements. The company has not disclosed a final issue schedule or the use of proceeds in the information provided.

Regulatory Framework for the Issue

The company has referred to the Companies Act, 2013, and SEBI's ICDR Regulations, 2018 for the proposed rights issue. It had also indicated that a draft letter of offer would be filed with SEBI and stock exchanges as part of the process. These filings and the final terms are important disclosure steps before investors can make an informed subscription decision. The committee was constituted to oversee the rights issue process and appoint necessary intermediaries. Any final announcement will need to set out the terms approved by the committee.

What to Watch After the Meeting

The October 26 meeting is the immediate event to watch for Fresita Proteins shareholders. The company is expected to disclose whether it has approved the issue price, entitlement ratio, record date, payment terms and final fundraising amount. The outcome will clarify the difference between the earlier ₹100 crore approval ceiling and the ₹90 crore proposal currently under consideration. It will also provide the timetable for eligible shareholders to assess participation. Until that disclosure is made, the proposed rights issue remains subject to final terms and procedural steps.